Monitor the company's use of the new facility for acquisitions or share repurchases, which could increase leverage. The next quarterly filing will show the initial drawdown and any impact on the net leverage ratio.
Price Chart
Executive Summary
West Pharmaceutical Services entered into a new $950 million unsecured credit agreement on October 26, 2026, consisting of a $750 million revolving credit facility and a $200 million term loan facility, and used a portion of the proceeds to repay and terminate its existing $130 million credit agreement. The new facility has a five-year term, provides increased liquidity and financial flexibility for general corporate purposes including acquisitions and share repurchases, and carries a net leverage covenant of 3.50x (4.00x during acquisition periods).
Key Financial Metrics
Key Facts
- New $950 million credit agreement entered on October 26, 2026, replacing the 2019 credit agreement
- Revolving credit facility of $750 million and term loan facility of $200 million
- Existing $130 million in outstanding debt under the prior facility was repaid in full
- No early termination penalties were incurred on the prior facility
- Five-year term ending October 26, 2031, with extension options for the revolver
- Unsecured borrowing with a net leverage covenant of 3.50x (4.00x during acquisition periods)
- Applicable margins range from 1.000% to 1.500% for SOFR/optional currency revolver loans and 1.125% to 1.750% for term SOFR loans
- Commitment fee on unused revolver ranges from 0.125% to 0.225%
- No subsidiary guarantors as of the effective date
Financial Impact
New $950 million credit facility replaces $130 million of outstanding debt, increasing total available borrowing capacity by $820 million. The $200 million term loan adds direct financial obligation with quarterly amortization starting March 2028.
Risk Factors
- Increased total debt capacity could lead to higher leverage if fully drawn
- Variable interest rate exposure on floating-rate borrowings
- Covenant compliance requires maintaining net leverage below 3.50x (4.00x during acquisition periods)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000105770-26-000114 |
| Document: wst-20261026.htm | 0000105770-26-000114 |
| Document: 0000105770-26-000114-index-headers.html | 0000105770-26-000114 |
| Document: 0000105770-26-000114-index.html | 0000105770-26-000114 |
| Document: 0000105770-26-000114.txt | 0000105770-26-000114 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $394.73 | awaiting T+60 | — | $398.29 (+0.90%) |
Oct 26, 2026 1d ago | Institutional Cluster | $394.73 | awaiting T+60 | — | $398.29 (+0.90%) |
Jul 23, 2026 13w ago | 8-K | $355.48 $383.02 | ▲ +7.75% | ▲ +3.19% | $398.29 (+12.04%) |
Jul 23, 2026 13w ago | Press Release | $355.48 $383.02 | ▲ +7.75% | ▲ +3.19% | $398.29 (+12.04%) |
Jul 7, 2026 16w ago | Press Release | $356.08 $370.76 | ▲ +4.12% | ▲ +2.13% | $398.29 (+11.85%) |
May 11, 2026 24w ago | 8-K | $311.82 $348.06 | ▼ −11.62% | ▼ −7.51% | $398.29 (−27.73%) |
Apr 27, 2026 26w ago | Insider Cluster | $300.93 $358.41 | ▲ +19.10% | ▲ +14.59% | $398.29 (+32.35%) |
Apr 27, 2026 26w ago | Insider Cluster | $300.93 $358.41 | ▲ +19.10% | ▲ +14.59% | $398.29 (+32.35%) |
Apr 27, 2026 26w ago | Insider Cluster | $300.93 $358.41 | ▲ +19.10% | ▲ +14.59% | $398.29 (+32.35%) |
Apr 27, 2026 26w ago | Insider Cluster | $300.93 $358.41 | ▲ +19.10% | ▲ +14.59% | $398.29 (+32.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers